February 28, 2022
1 minute read
Over the past decades, ophthalmology has been a leader in exploring advanced technologies to combat blinding diseases, and innovative gene-based strategies have shown promising results.
This blog hopes to discuss the latest news in this field but also topics relevant to the ophthalmological community, including the surgical methods that enable the delivery of treatments and the issues surrounding them.
Since the time the human DNA sequence was deciphered, genetic discovery has identified more than 270 genes known to cause rare forms of inherited eye diseases, according to RetNet, and a battery of predisposing genetic markers for more common diseases, such as age-related diseases. macular degeneration and glaucoma, has also been established. This genetic information has given doctors and scientists the tools to explore gene-based therapeutic strategies for eye diseases that still represent a significant unmet medical need.
Strategies in genetic medicine derive from the basic theory that replacing, modifying or adding specific genetic sequences can reverse, prevent or delay the natural history of the target disease and can therefore have a significant impact on the quality of the patient’s life.
This blog aims to educate the reader on the basic principles of genomic medicine, the strategies that currently exist in gene therapy, the surgical modalities needed to deliver them, possible surgical complications, and the diseases that new treatments hope to combat. In addition, other topics will be presented, such as the need for appropriate endpoints in clinical development, news on clinical trial safety, and the role of the vitreoretinal surgeon in genomic medicine. We will also feature guest bloggers from the vitreoretinal field, the perspective of patient advocates, and exciting new developments from retinal science researchers. Today, gene-based medicine is no longer an aspiration or a fantasy but a reality. Obtaining information about these innovative genomic drugs will help doctors better inform their patients about treatment options or clinical trials they could participate in.